Findings from a new study show that pharmacologically inhibiting the H6PD protein can reverse drug resistance in human-derived preclinical models of enzalutamide-resistant prostate cancer.
Improved imaging technology and a shift in diagnostic practice are making transperineal fusion-guided biopsy a popular approach among urologists at Cleveland Clinic.
Findings from a 20-year study suggest that genomic testing can predict long-term outcomes of prostate cancer.
For select patients, high-intensity focused ultrasound, a type of focal therapy for treating localized prostate cancer, may be an attractive alternative to more traditional treatments, such as surgery and radiation.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Since 2012, more U.S. urologists have said they’d refer their most complex urology cases to Cleveland Clinic than to any other medical center. Eric Klein, MD, Chair of Glickman Urological & Kidney Institute, explains why.
An Italian-led study published earlier this year reported that androgen deprivation therapy may play a protective role against the risk of SARS-CoV-2 infection. Using an expansive enterprise-wide COVID-19 testing registry, Cleveland Clinic researchers set out to validate this report. Eric Klein, MD, discusses their findings.
Cleveland Clinic has begun enrolling patients in a prospective, national clinical study designed to evaluate the use of a multi-cancer early detection test, which has demonstrated the ability to detect more than 50 cancers through a single blood draw.
Findings from a new study show that time-to-treatment, at least in the short term, is not significantly associated with adverse outcomes in patients with high-risk prostate cancer. Eric Klein, MD, Chair of the Glickman Urological and Kidney Institute and a co-author of the study, comments on the implications of these findings.
A new study examines the rate of downgrading in patients with high-grade prostate cancer on initial biopsy. Eric Klein, MD, Chair of Glickman Urological & Kidney Institute and co-author of the study, comments on the investigation and shares clinical insights.
Cleveland Clinic is now offering the IsoPSA™ test, a novel prostate-specific antigen assay, for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.